Answers are grounded in this paper and cite their sources.
An amperometric biosensor based on genetically-modified enzymes was used for the in situ detection of trace vapours from a number of explosive compounds. The vapour samples that were generated from a purpose-built vapour generator were collected and pre-concentrated using a trap able to concentrate samples at a rate of 60-fold per minute of sampling. The amperometric biosensor achieved a remarkably low vapour detection limit of 6 parts per trillion from a room temperature sample. The specific activity of the reported enzyme toward a number of explosive compounds was also confirmed using absorbance measurements.
No takes yet. Share an insight, caveat, or question.
Gwenin et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: